Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733742 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2ESR2NR1H2MAPT | |
| SCHEMBL734541 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2ESR2NR1H2MAPT | |
| SCHEMBL15227433 | 0.83 | USP2 (0.41) | USP2SMN1; SMN2ESR2NR1H2MAPT | |
| SCHEMBL28441771 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2ESR2NR1H2MAPT | |
| SCHEMBL21241481 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2ESR2NR1H2MAPT | |
| SCHEMBL104498 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2ESR2NR1H2MAPT | |
| Ammonia Solution, Strong SCHEMBL28305195 | 0.81 | USP2 (0.42) | USP2SMN1; SMN2ESR2NR1H2MAPT | |
| SCHEMBL30841276 | 0.80 | USP2 (0.41) | USP2SMN1; SMN2ESR2NR1H2MAPT | |
| SCHEMBL31094705 | 0.80 | USP2 (0.41) | USP2SMN1; SMN2ESR2NR1H2MAPT | |
| SCHEMBL31715320 | 0.80 | USP2 (0.39) | USP2SMN1; SMN2ESR2NR1H2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119076-B | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | 默沙东有限责任公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-3788043-B1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-11332463-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210070745-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2021-03-11 | — | — | US | disclosed |
| CN-112119076-A | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | 默沙东公司 | 2020-12-22 | — | — | CN | disclosed |
| EP-2358704-A1 | 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase | Pfizer Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | PFIZER INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010049841-A1 | 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | PFIZER INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | MEINGASSNER JOSEF GOTTFRIED | 2009-09-10 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | STS, ARSA, CYP17A1 | USP2 1531/4885SMN1; SMN2 2881/4885ESR2 988/4885 |
| US-11332463-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA6 | USP2 4415/4885SMN1; SMN2 2483/4885ESR2 1092/4885 |
| US-20210070745-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | USP2 4415/4885SMN1; SMN2 2483/4885ESR2 1092/4885 |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | STS, SERPINB1, MPO | USP2 1029/4885SMN1; SMN2 3691/4885ESR2 568/4885 |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | FAAH, FAAH2, APEH | USP2 991/4885SMN1; SMN2 1061/4885ESR2 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.